John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

Daratumumab: the first anti-CD38 monoclonal antibody for the treatment of multiple myeloma Ahead of print

Figures

  • Figure 1
  • Figure 2

Tables

Authors
1 CHU Nantes
Service d’hématologie
Nantes
France
2 CRCNIA, Inserm
CNRS, Université de Nantes
Nantes
France
3 IUCT Oncopole
Service d’hématologie
Toulouse
France
4 IUCT Oncopole
Équipe 13 CRCT
Toulouse
France
5 CHU Poitiers
Service d’hématologie et thérapie
cellulaire
Poitiers
France
6 CIC Inserm U1402
Poitiers
France
* Tirés à part

In recent years, the use of proteasome inhibitors and immunomodulatory drugs for the treatment of myeloma has contributed to the dramatic improvement in patient survival. However, the disease continues to relapse and new classes of drugs are needed. Daratumumab is the first anti-CD38 monoclonal antibody approved for the treatment of relapsing myeloma. Daratumumab induces myeloma cell death through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). Daratumumab binding also directly induces apoptosis of myeloma cells by decreasing CD38 enzymatic functions. Daratumumab presents an excellent safety profile. Moderate-grade infusion-related reactions, occurring mostly during the first infusion, are the main treatment-emergent adverse event. In the context of daratumumab treatment, attention should be paid to interference with blood compatibility testing and response assessment. Here, the authors discuss the published data regarding the mechanism of action, safety, and clinical efficacy of the CD38-targeted monoclonal antibody, daratumumab, for treating patients with multiple myeloma.